Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem-cell support for refractory/relapsed multiple myeloma.

Carolina Perrone MarquesDanielle OvigliMariana Nassif KerbauyAna Carolina de Almeida SilveiraRicardo HelmanCinthya Correa da SilvaAndreza Alice Feitosa RibeiroNelson Hammerschlak Leonardo Javier Arcuri

Published in: European journal of haematology (2024)

Intensive chemotherapy can decrease disease burden in patients with relapsed/refractory MM, and stem-cell support can successfully decrease toxicities and treatment-related mortality associated with these regimens and may be a good bridging option.

Keyphrases

multiple myeloma
hematopoietic stem cell
stem cells
acute lymphoblastic leukemia
acute myeloid leukemia
locally advanced
hodgkin lymphoma
diffuse large b cell lymphoma
cardiovascular events
cardiovascular disease
radiation therapy
rectal cancer
cell therapy
drug induced
replacement therapy